Novo Nordisk A/S (NYSE:NVO) Downgraded by TD Cowen to “Hold”

TD Cowen lowered shares of Novo Nordisk A/S (NYSE:NVO) from a buy rating to a hold rating in a research report released on Tuesday morning, MarketBeat.com reports. They currently have $42.00 target price on the stock.

Other analysts also recently issued reports about the stock. Zacks Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, February 9th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Nordea Equity Research downgraded Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Finally, Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Four equities research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and an average target price of $49.93.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $38.73 on Tuesday. Novo Nordisk A/S has a one year low of $35.85 and a one year high of $82.57. The company has a 50-day moving average of $50.93 and a two-hundred day moving average of $52.11. The stock has a market cap of $172.92 billion, a price-to-earnings ratio of 11.16 and a beta of 0.73. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The business also recently announced a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 23.63%.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of hedge funds have recently modified their holdings of the stock. True Wealth Design LLC grew its stake in Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares in the last quarter. Guerra Advisors Inc purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth about $25,000. Godfrey Financial Associates Inc. acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $25,000. WealthCollab LLC lifted its holdings in shares of Novo Nordisk A/S by 93.5% during the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after buying an additional 260 shares during the last quarter. Finally, American National Bank & Trust bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $28,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Capacity and production investment — Novo is expanding manufacturing in Ireland with ~ $506m to raise oral GLP‑1 output to meet global demand, which supports longer‑term volume growth and supply resilience. Novo expands manufacturing (InsiderMonkey)
• Positive Sentiment: Distribution partnership — Novo agreed to supply Wegovy/Ozempic through Hims & Hers’ telehealth platform, ending a legal dispute and opening a digital channel that could broaden U.S. access and sales. That deal helped calm one litigation front and may support volume. Novo-Hims deal (Reuters)
• Positive Sentiment: Share repurchase — Novo confirmed ongoing share buybacks (part of up to DKK15bn programme), which is supportive for shareholder returns and EPS. Share repurchase programme (GlobeNewswire)
• Neutral Sentiment: Past earnings vs. guidance — Novo beat Q4 consensus on revenue and EPS but earlier issued weak FY2026 guidance that pressured the stock; investors now weigh strong recent results against management’s cautious full‑year outlook. Q4 results & guidance (Seeking Alpha)
• Negative Sentiment: FDA warning letter — The U.S. FDA issued a warning letter after an inspection tied to Plainsboro (early 2025) citing failures in post‑marketing safety reporting for semaglutide products; the regulator flagged potential unreported adverse events including two deaths and a suicide — a material safety/regulatory risk that spooked investors. FDA warning (Reuters) Potential unreported side effects (Forbes)
• Negative Sentiment: Legal / investor risk — A law firm (Pomerantz) has launched an investigation on behalf of investors, increasing potential litigation/legal-cost overhangs. Investor investigation (GlobeNewswire)
• Negative Sentiment: Analyst downgrades and pipeline concerns — TD Cowen cut NVO to Hold and other analysts flagged the pipeline as “not poised to blunt semaglutide loss‑of‑exclusivity” and rising competitive pressure from new GLP‑1 entrants, pressuring forward expectations and valuation. Pipeline downgrade (Yahoo Finance)
• Negative Sentiment: Market reaction / sector weakness — Healthcare indices were weaker intraday as investors rotated away from GLP‑1 names amid safety/regulatory headlines and heightened competition; that broad sentiment hit NVO alongside the specific company news. Sector decline (Yahoo Finance)

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.